KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,873,662 | -46.9% | 341,081 | -33.1% | 0.93% | -53.1% |
| Q2 2023 | $20,470,143 | -36.5% | 509,461 | -32.5% | 1.98% | -19.8% |
| Q1 2023 | $32,243,581 | -19.5% | 755,119 | -9.5% | 2.47% | -4.8% |
| Q4 2022 | $40,048,344 | +19.9% | 833,993 | -6.0% | 2.60% | +20.1% |
| Q3 2022 | $33,391,000 | +26.7% | 887,592 | -6.9% | 2.16% | +63.6% |
| Q2 2022 | $26,354,000 | -43.6% | 953,801 | +11.1% | 1.32% | -36.1% |
| Q1 2022 | $46,698,000 | -4.6% | 858,730 | +2.7% | 2.07% | +20.0% |
| Q4 2021 | $48,938,000 | +62.7% | 836,398 | +10.0% | 1.72% | +81.6% |
| Q3 2021 | $30,081,000 | +18.3% | 760,383 | +27.0% | 0.95% | +31.1% |
| Q2 2021 | $25,434,000 | -10.2% | 598,880 | +30.1% | 0.72% | -12.7% |
| Q1 2021 | $28,336,000 | -24.8% | 460,372 | -13.9% | 0.83% | -29.1% |
| Q4 2020 | $37,705,000 | +253.1% | 534,514 | +93.1% | 1.17% | +257.2% |
| Q3 2020 | $10,677,000 | +3.5% | 276,827 | +0.7% | 0.33% | +5.1% |
| Q2 2020 | $10,315,000 | – | 275,000 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |